1 research outputs found
Abuse-deterrent Opioid Formulations
- Author
- Institute for Clinical and Economic Review: Abuse-deterrent formulations of opioids: Effectiveness and value
- Multistate Insider: States have stalled on potential opioid abuse solution: Deterrent formulation drugs
- Office of National Drug Control Policy USA: National Drug Control Strategy
- Office of National Drug Control Policy USA: National Heroin Task Force final report and recommendations
- Pfizer Inc.: Embeda® (morphine sulfate and naltrexone HCl)
- Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality: Results 2015 National Survey on Drug Use and Health: Detailed tables
- U.S. Food and Drug Administration: Abuse-deterrent opioids—evaluation and labeling. Guidance for industry
- U.S. Food and Drug Administration: Briefing document: Joint meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee
- U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Data and methods for evaluating the impact of opioid formulations with properties designed to deter abuse in the postmarket setting
- U.S. Food and Drug Administration: Determination that the OxyContin (oxycodone hydrochloride) products covered by New Drug Application 20–553 were withdrawn from sale for reasons of safety or effectiveness
- U.S. Food and Drug Administration: FDA actions on OxyContin products
- U.S. Food and Drug Administration: FDA approves Targiniq ER with abuse-deterrent properties
- U.S. Food and Drug Administration: FDA requests removal of Opana ER for risks related to abuse
- U.S. Food and Drug Administration: Opioids action plan
- U.S. Food and Drug Administration: Postmarketing safety issues related to reformulated Opana ER®
- U.S. Food and Drug Administration: Sponsor briefing document: Arymo™ ER (morphine sulfate) extended-release tablets
- U.S. Food and Drug Administration: Summary review for regulatory action: Hysingla® ER
- Publication venue
- 'Ovid Technologies (Wolters Kluwer Health)'
- Publication date
- Field of study
No full text
